Johnson & Johnson Sees Unusual Options Activity as $845K Call Contract Hits Near 52-Week High

By TrendSpider Editor

Johnson & Johnson is drawing attention in the options market today, with two unusual contracts totaling $1,151,937.80 in combined premium flagged across puts and calls. The dominant position is a $845,000 in-the-money call at the $270 strike, pointing to notable directional interest with JNJ shares

Johnson & Johnson Sees Unusual Options Activity as $845K Call Contract Hits Near 52-Week High

Johnson & Johnson is drawing attention in the options market today, with two unusual contracts totaling $1,151,937.80 in combined premium flagged across puts and calls. The dominant position is a $845,000 in-the-money call at the $270 strike, pointing to notable directional interest with JNJ shares currently trading at $272. The stock sits near the upper end of its 52-week range of $174.12 to $281.07, suggesting traders are positioning with the stock already deep into a strong recovery.

Key Drivers of the JNJ Stock Move

• Main Catalyst: Two unusual options contracts were flagged today, combining for $1,151,937.80 in total premium. A large call at the $270 strike expiring October 16, 2026 saw 1,000 contracts trade against an open interest reading of just 27% above baseline, while a put at the $310 strike expiring December 18, 2026 printed 78 contracts with open interest surging 3,900% above normal levels.
• Bull Case: The $845,000 call at $270 is already in the money with JNJ at $272 and expires in just under three weeks on October 16, 2026. The size and in-the-money status of this position suggests a trader is making a high-conviction near-term directional bet that JNJ holds or extends above $270, with the stock only $9.07 away from its 52-week high of $281.07.
• Bear Case: The in-the-money put at the $310 strike expiring December 18, 2026 is noteworthy despite its smaller size of 78 contracts and $306,937.80 in premium. With JNJ trading at $272, this put is deeply in the money, meaning it profits if the stock remains well below $310. The explosive 3,900% open interest reading implies this strike had almost no prior activity, and its sudden appearance could signal a hedging operation or a bet on a meaningful pullback before year end.

The forward setup for JNJ is a tug of war between short-term momentum and longer-term uncertainty. The stock's 0.30% gain today is modest, but the proximity to the 52-week high of $281.07 makes the next several weeks a critical test of whether buyers can push through resistance. The near-term call expiring October 16, 2026 will resolve quickly, making price action in the first two weeks of October especially important to watch. Traders should also note that the deeply in-the-money December put at $310 introduces a bearish counterweight that could reflect institutional hedging activity into the back half of the year.

JNJ Unusual Options Activity

• Contract 1: Call | Strike: $270 | Expiry: October 16, 2026 | Volume: 1,000 | Open Interest: 27% above baseline | Status: In the Money
• Contract 2: Put | Strike: $310 | Expiry: December 18, 2026 | Volume: 78 | Open Interest: 3,900% above baseline | Status: In the Money

Total unusual contracts flagged: 2. Total combined premium across both positions: $1,151,937.80. The call dominates the flow at $845,000, while the put accounts for $306,937.80. The outsized open interest reading on the December put at 3,900% is the most statistically significant figure in today's activity, indicating that the $310 strike had virtually no prior positioning before today.

JNJ Seasonality

Late September and early October have historically been a transitional period for large-cap healthcare names, with quarterly earnings cycles and year-end portfolio positioning often driving elevated volatility. With JNJ options activity picking up heading into the final quarter of 2026, the timing of both the October and December expirations aligns with periods that have historically seen increased institutional activity in the sector.

JNJ Relative Performance

JNJ's 0.30% gain today is a mild outperformer relative to typical flat trading sessions in large-cap pharma. With shares at $272 and the 52-week range spanning from $174.12 to $281.07, the stock has recovered approximately 56% from its annual low, placing it in the top decile of its own range heading into the final quarter of 2026. That positioning near multi-month highs adds significance to both the bullish near-term options flow and the bearish longer-dated put activity flagged today.